Fingolimod induced fulminant liver failure requiring liver transplantation: A case report.

Acute liver failure drug-induced liver injury fingolimod liver transplantation multiple sclerosis

Journal

Hepatology forum
ISSN: 2757-7392
Titre abrégé: Hepatol Forum
Pays: Turkey
ID NLM: 9918351171306676

Informations de publication

Date de publication:
Mar 2023
Historique:
received: 28 08 2022
revised: 25 01 2023
accepted: 21 02 2023
medline: 30 5 2023
pubmed: 30 5 2023
entrez: 30 5 2023
Statut: epublish

Résumé

Fingolimod has been used for about ten years to treat multiple recurrent sclerosis. It has been reported that Fingolimod causes an elevation in liver enzymes. In this case report, the clinical and laboratory parameters improved after discontinuation of the drug. However, there is no publication in the literature regarding acute liver failure and liver transplantation following Fingolimod treatment. In this article, we presented a 33 - year - old female patient who developed acute liver failure and underwent liver transplantation after Fingolimod treatment for recurrent multiple sclerosis.

Identifiants

pubmed: 37250929
doi: 10.14744/hf.2022.2022.0033
pii: hf-4-074
pmc: PMC10209975
doi:

Types de publication

Case Reports

Langues

eng

Pagination

74-77

Informations de copyright

© Copyright 2023 by Hepatology Forum.

Déclaration de conflit d'intérêts

The authors have no conflict of interest to declare.

Références

Hepatology. 2008 Apr;47(4):1401-15
pubmed: 18318440
J Neurol Neurosurg Psychiatry. 2016 May;87(5):468-75
pubmed: 26111826
Hepatology. 2012 Mar;55(3):965-7
pubmed: 22213561
J Neuroimmunol. 2015 Dec 15;289:93-7
pubmed: 26616877
Am J Manag Care. 2013 Feb;19(2 Suppl):S15-20
pubmed: 23544716
N Engl J Med. 2010 Feb 4;362(5):402-15
pubmed: 20089954
Int Immunopharmacol. 2006 Dec 20;6(13-14):1902-10
pubmed: 17161343
Lancet Neurol. 2014 Jun;13(6):545-56
pubmed: 24685276
Semin Liver Dis. 2008 May;28(2):142-52
pubmed: 18452114
Mult Scler Relat Disord. 2014 Jul;3(4):494-504
pubmed: 25877062
N Engl J Med. 2010 Feb 4;362(5):387-401
pubmed: 20089952
Annu Rev Immunol. 2005;23:683-747
pubmed: 15771584
Mult Scler. 2019 Oct;25(12):1633-1640
pubmed: 30230957
J Formos Med Assoc. 2020 Apr;119(4):886-887
pubmed: 31679907
CNS Drugs. 2018 Mar;32(3):269-287
pubmed: 29600441

Auteurs

Ali Riza Caliskan (AR)

Department of Gastroenterology, Adiyaman Training and Research Hospital, Adiyaman, Turkiye.

Muhsin Murat Muhip Harputluoglu (MM)

Department of Gastroenterology, Inonu University School of Medicine, Malatya, Turkiye.

Emine Samdanci (E)

Department of Pathology, Inonu University School of Medicine, Malatya, Turkiye.

Salih Cirik (S)

Department of Internal Medicine, Malatya Training and Research Hospital, Malatya, Turkiye.

Sezai Yilmaz (S)

Department of General Surgery, Liver Transplantation Institute, Inonu University School of Medicine, Malatya, Turkiye.

Classifications MeSH